B-CELL ACTIVATION IN CLINICALLY QUIESCENT SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE) IS RELATED TO IMMUNOGLOBULIN LEVELS, BUT NOT TO LEVELS OF ANTI-DSDNA, NOR TO CONCURRENT T-CELL ACTIVATIONSPRONK, PE., VANDERGUN, BTF., LIMBURG, PC. & KALLENBERG, CGM., Jul-1993, In : Clinical and Experimental Immunology. 93, 1, p. 39-44 6 p.
Research output: Contribution to journal › Article › Academic › peer-review
In clinically quiescent SLE hypergammaglobulinaemia, presence of autoantibodies, and increased soluble IL-2 receptors (sIL-2R) have been reported, suggesting persistent B as well as T cell activation. In contrast, the primary immune response to test antigens is markedly decreased. To analyse these phenomena at a cellular level, we undertook a cross-sectional study on 13 non-active SLE patients and 15 controls. We determined the composition of lymphocyte subsets with special attention to activation markers (CD25, HLA-DR, CD38) and the presence of naive T cells (CD45RO-), and related those findings to serological parameters. In non-active SLE patients the expression of activation markers on B cells and T cells was higher than in normal controls (P less-than-or-equal-to 0-02), but was not interrelated. Percentages of activated B cells in SLE were related to levels of total IgG (P <0.02) and IgM (P <0-02) but not to anti-dsDNA, suggesting a disordered immune system also in clinically quiescent SLE. Numbers of CD4+ cells (P
|Number of pages||6|
|Journal||Clinical and Experimental Immunology|
|Publication status||Published - Jul-1993|
- SYSTEMIC LUPUS ERYTHEMATOSUS, LYMPHOCYTE ACTIVATION, ANTI-DSDNA, HYPERGAMMAGLOBULINEMIA, INTERLEUKIN-2 RECEPTOR, ANTIBODIES, DISEASE, INVITRO, EXACERBATIONS, LYMPHOCYTES, SM